|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Antibody-Drug Conjugates in Advanced Urothelial Cancer: Current Landscape and Future Directions |
Matthew Galsky, MD, FASCO, Neal Shore, MD, FACS
Ashish Kamat hosts a discussion with Matthew Galsky and Neal Shore on the latest advancements in ADCs for bladder cancer. Dr. Galsky provides an overview of ADCs, highlighting the components and mechanisms of enfortumab vedotin and sacituzumab govitecan, and discusses promising results from recent trials. |
|
|
|
|
|
|
|
|
|
|
| EV-302 Subgroup Analysis: Improved Outcomes for Cisplatin-Ineligible Advanced Urothelial Cancer Patients |
Michiel Simon Van der Heijden, MD, Ph.D.
Zach Klaassen discusses the findings of the EV-302/KEYNOTE-A39 trial with Michiel Simon Van der Heijden. The trial addresses a critical gap in treatment for cisplatin-ineligible patients with advanced urothelial cancer. |
|
|
|
|
|
|
|
|
|
|
| Outcomes of Enfortumab Vedotin After Platinum and Avelumab in Bladder Cancer |
Amanda Nizam, MD
Amanda Nizam presents findings from the UNITE study, exploring enfortumab vedotin's (EV) efficacy in patients with advanced urothelial carcinoma post-platinum-based chemotherapy and maintenance avelumab. This retrospective analysis, involving 633 patients across 16 US sites, reveals that EV's outcomes are consistent with previous trials, even after maintenance avelumab. |
|
|
|
|
|
|
|
|
|
|
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy
|
| Daniel Petrylak, MD, Scott Tagawa, MD, Rohit Jain, MD et al.
|
| Sacituzumab govitecan is a Trop-2–directed antibody-drug conjugate with an SN-38 payload, approved for patients with locally advanced or metastatic urothelial cancer who progressed after platinum-based chemotherapy and a checkpoint inhibitor. Here, the authors report results from Cohort 2 of TROPHY-U-01 trial, evaluating the efficacy and safety of SG in patients with mUC.
|
|
|
|
|
|
| Is TROP2 Just Not What We Thought It Was for Bladder Cancer? Where to Go after TROPiCS-04?
|
| Evan Yu, MD |
| The TROPiCS-04 trial showed that sacituzumab govitecan, a TROP2-targeting antibody-drug conjugate, did not improve overall survival in heavily pre-treated urothelial cancer patients, raising questions about its efficacy and safety. Despite these results, the high expression of TROP2 in bladder cancer suggests it remains a viable target. Future studies should focus on optimizing sacituzumab govitecan use, exploring other TROP2-targeting drugs, and incorporating growth factor prophylaxis to mitigate adverse events.
|
|
|
|
|
|
|
|
|
|
|
Antibody-Drug Conjugate Combination Therapy in Patients with Metastatic Urothelial Cancer - Expert Commentary
|
| Bishoy Faltas, MD |
| A phase I trial combining enfortumab vedotin and sacituzumab govitecan for metastatic urothelial carcinoma showed promising results, with a 70% objective response rate and 87% of patients experiencing tumor shrinkage. Despite a high rate of grade 3 or higher adverse events, including neutropenia and anemia, the combination demonstrated potential efficacy, with 12-month progression-free survival and overall survival rates of 41% and 86%, respectively. Further larger-scale studies are needed to refine dosing, optimize treatment sequencing, and manage neuropathy-related toxicities. |
|
|
|
|
|
| Perioperative Sacituzumab Govitecan Alone or in Combination with Pembrolizumab for Patients with Muscle-invasive Urothelial Bladder Cancer: SURE-01/02 Interim Results |
| Antonio Cigliola, MD |
| Antonio Cigliola presents interim results from the SURE-01/02 trials evaluating sacituzumab govitecan alone or combined with pembrolizumab for MIBC. In the SURE-01 trial, SG as a monotherapy showed promising results, with a pathologic complete response rate of 36.4% among those who underwent radical cystectomy. However, high rates of grade 3-4 neutropenia and diarrhea led to protocol amendments, including dose reduction and the use of prophylactic G-CSF, which improved the safety profile. |
|
|
|
|
|
| Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer - Beyond the Abstract |
| Vincent D’Andrea, Yuzhen Zhou, and Kent Mouw |
| This preclinical study investigated the effects of combining enfortumab vedotin and sacituzumab govitecan, two antibody-drug conjugates, with radiation therapy in bladder cancer models. Results showed that combining these ADCs with RT led to additive cytotoxic effects, increased DNA damage, and reduced tumor size and proliferation compared to using each treatment alone. These findings suggest that EV and SG, when combined with RT, could serve as effective radiosensitizers in MIBC, providing a strong rationale for developing clinical trials to explore this combination in a bladder-sparing treatment approach. |
|
|
|
|
|
|
|
|
|
|
